This page is part of the FHIR Specification (v3.3.0: R4 Ballot 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions
. Page versions: R5 R4B R4
| Biomedical Research and Regulation Work Group | Maturity Level: N/A | Ballot Status: Informative |
Definition for Code System ResearchStudyPhase
{
"resourceType": "CodeSystem",
"id": "research-study-phase",
"meta": {
"lastUpdated": "2018-04-03T12:05:46.262+10:00"
},
"text": {
"status": "generated",
"div": "<div>!-- Snipped for Brevity --></div>"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode": "brr"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-ballot-status",
"valueString": "Draft"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
"valueInteger": 1
}
],
"url": "http://hl7.org/fhir/research-study-phase",
"identifier": {
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.4.642.1.822"
},
"version": "3.3.0",
"name": "ResearchStudyPhase",
"status": "draft",
"experimental": false,
"date": "2018-04-03T12:05:46+10:00",
"publisher": "HL7 (FHIR Project)",
"contact": [
{
"telecom": [
{
"system": "url",
"value": "http://hl7.org/fhir"
},
{
"system": "email",
"value": "fhir@lists.hl7.org"
}
]
}
],
"description": "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.",
"caseSensitive": true,
"valueSet": "http://hl7.org/fhir/ValueSet/research-study-phase",
"content": "complete",
"concept": [
{
"code": "n-a",
"display": "N/A",
"definition": "Trials without phases (for example, studies of devices or behavioral interventions)."
},
{
"code": "early-phase-1",
"display": "Early Phase 1",
"definition": "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0."
},
{
"code": "phase-1",
"display": "Phase 1",
"definition": "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients."
},
{
"code": "phase-1-phase-2",
"display": "Phase 1/Phase 2",
"definition": "Trials that are a combination of phases 1 and 2."
},
{
"code": "phase-2",
"display": "Phase 2",
"definition": "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks."
},
{
"code": "phase-2-phase-3",
"display": "Phase 2/Phase 3",
"definition": "Trials that are a combination of phases 2 and 3."
},
{
"code": "phase-3",
"display": "Phase 3",
"definition": "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug."
},
{
"code": "phase-4",
"display": "Phase 4",
"definition": "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use."
}
]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.